This brain cancer trial pairs a new imaging approach with standard treatment (bevacizumab). The trial is evaluating the use of two contrast-enhanced MRI exams, one before treatment begins and the other after two weeks. There is evidence from smaller trials that early use of contrast MRI to measure changes in the amount of blood in the tumor is a better and faster way than the current method to identify which patients are benefiting from bevacizumab. This earlier measure could also help those for whom the therapy is not working, allowing them to move on to try other treatments. Currently, physicians measure response after three months of treatment.
Physician and Research Staff Educational Material
This material is intended for promotional use among health care professionals and is NOT intended for use as patient educational material.
Physicians and Locations Interested in Opening the Trial: Send an email
Information and Assistance from the National Cancer Institute
ClinicalTrials.gov ID: NCT03115333